BioCentury | Sep 1, 2014
Clinical News

Brilacidin: Completed Phase IIb enrollment

...year. In September 2013, the company gained the product through its acquisition of assets from PolyMedix Inc....
BioCentury | Jul 14, 2014
Clinical News

Brilacidin: Phase IIb ongoing

...last year. In September, the company gained the product through its acquisition of assets from PolyMedix Inc....
BioCentury | Feb 24, 2014
Clinical News

Brilacidin: Phase IIb started

...last year. In September, the company gained the product through its acquisition of assets from PolyMedix Inc....
BioCentury | Dec 23, 2013
Clinical News

Brilacidin: Phase IIb start

...last year. In September, the company gained the product through its acquisition of assets from PolyMedix Inc....
...Court for the District of Delaware in April. Cellceutix said it also plans to complete PolyMedix's...
BioCentury | Sep 23, 2013
Company News

Cellceutix infectious news

...Cellceutix said it also plans to complete PolyMedix's application for an IND for a Phase II...
...The company acquired the synthetic defensing mimetic bactericidal antibiotic through its acquisition of assets from PolyMedix Inc....
BioCentury | Sep 16, 2013
Company News

Cellceutix, PolyMedix deal

...Cellceutix acquired PolyMedix's assets, including the defunct biotech's pipeline of nine compounds as well as substantial...
...including the defunct biotech's pipeline of nine compounds as well as substantial equipment assets at PolyMedix's...
...or from previously approved products (see BioCentury, June 28, 2012). In April, PolyMedix and its PolyMedix...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...27 Japanese biotechs is up 164% for the year despite gaining only 0.3% in 2Q13 PolyMedix Inc....
...Inc. (Tokyo:4587), Tokyo, Japan Pharmos Corp. (Pink:PARS), Iselin, N.J. Polydex Pharmaceuticals Ltd. (Pink:POLXF), Toronto, Ontario PolyMedix Inc....
BioCentury | Apr 15, 2013
Company News

PolyMedix infectious news

...PolyMedix and its PolyMedix Pharmaceuticals Inc. subsidiary filed for Chapter 7 bankruptcy in the U.S. Bankruptcy...
...31, 2012, the company had $4.6 million in assets and $11.3 million in total liabilities. PolyMedix...
...was appointed interim president and CEO in January (see BioCentury, Feb. 4). In early March, PolyMedix...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...the Gen-Probe acquisition and an additional $35M by the end of the third year 1/23/13 PolyMedix Inc....
BioCentury | Mar 11, 2013
Financial News

PolyMedix proposes follow-on

PolyMedix Inc. (OTCBB:PYMX), Radnor, Pa. Business: Infectious, Cardiovascular Date announced: 3/7/13 Type: Follow-on To be raised: About $25 million Shares: TBD Price prior: $0.12 Underwriters: Aegis Capital; Fordham Financial Management; Emerging Growth Equities Note: The...
Items per page:
1 - 10 of 100
BioCentury | Sep 1, 2014
Clinical News

Brilacidin: Completed Phase IIb enrollment

...year. In September 2013, the company gained the product through its acquisition of assets from PolyMedix Inc....
BioCentury | Jul 14, 2014
Clinical News

Brilacidin: Phase IIb ongoing

...last year. In September, the company gained the product through its acquisition of assets from PolyMedix Inc....
BioCentury | Feb 24, 2014
Clinical News

Brilacidin: Phase IIb started

...last year. In September, the company gained the product through its acquisition of assets from PolyMedix Inc....
BioCentury | Dec 23, 2013
Clinical News

Brilacidin: Phase IIb start

...last year. In September, the company gained the product through its acquisition of assets from PolyMedix Inc....
...Court for the District of Delaware in April. Cellceutix said it also plans to complete PolyMedix's...
BioCentury | Sep 23, 2013
Company News

Cellceutix infectious news

...Cellceutix said it also plans to complete PolyMedix's application for an IND for a Phase II...
...The company acquired the synthetic defensing mimetic bactericidal antibiotic through its acquisition of assets from PolyMedix Inc....
BioCentury | Sep 16, 2013
Company News

Cellceutix, PolyMedix deal

...Cellceutix acquired PolyMedix's assets, including the defunct biotech's pipeline of nine compounds as well as substantial...
...including the defunct biotech's pipeline of nine compounds as well as substantial equipment assets at PolyMedix's...
...or from previously approved products (see BioCentury, June 28, 2012). In April, PolyMedix and its PolyMedix...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...27 Japanese biotechs is up 164% for the year despite gaining only 0.3% in 2Q13 PolyMedix Inc....
...Inc. (Tokyo:4587), Tokyo, Japan Pharmos Corp. (Pink:PARS), Iselin, N.J. Polydex Pharmaceuticals Ltd. (Pink:POLXF), Toronto, Ontario PolyMedix Inc....
BioCentury | Apr 15, 2013
Company News

PolyMedix infectious news

...PolyMedix and its PolyMedix Pharmaceuticals Inc. subsidiary filed for Chapter 7 bankruptcy in the U.S. Bankruptcy...
...31, 2012, the company had $4.6 million in assets and $11.3 million in total liabilities. PolyMedix...
...was appointed interim president and CEO in January (see BioCentury, Feb. 4). In early March, PolyMedix...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...the Gen-Probe acquisition and an additional $35M by the end of the third year 1/23/13 PolyMedix Inc....
BioCentury | Mar 11, 2013
Financial News

PolyMedix proposes follow-on

PolyMedix Inc. (OTCBB:PYMX), Radnor, Pa. Business: Infectious, Cardiovascular Date announced: 3/7/13 Type: Follow-on To be raised: About $25 million Shares: TBD Price prior: $0.12 Underwriters: Aegis Capital; Fordham Financial Management; Emerging Growth Equities Note: The...
Items per page:
1 - 10 of 100